1ERR image
Entry Detail
PDB ID:
1ERR
Title:
HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
1997-09-08
Release Date:
1998-09-16
Method Details:
Experimental Method:
Resolution:
2.60 Å
R-Value Free:
0.29
R-Value Work:
0.21
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:ESTROGEN RECEPTOR
Chain IDs:A, B
Chain Length:253
Number of Molecules:2
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
CCS A CYS CARBOXYMETHYLATED CYSTEINE
Ligand Molecules
Primary Citation
Molecular basis of agonism and antagonism in the oestrogen receptor.
Nature 389 753 758 (1997)
PMID: 9338790 DOI: 10.1038/39645

Abstact

Oestrogens are involved in the growth, development and homeostasis of a number of tissues. The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER). Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of molecular events culminating in the activation or repression of target genes. Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery. Here we report the crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17beta-oestradiol, and the selective antagonist raloxifene, at resolutions of 3.1 and 2.6 A, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties. Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes. In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.

Legend

Protein

Chemical

Disease

Primary Citation of related structures